ArticleJournal of applied toxicology : JAT2026
Deciphering the Pathogenic Cascade of Acrolein-Induced Lung Injury: From Molecular Insult to Organ Failure.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acrolein, a major toxicant in fire and industrial smoke, induces fatal acute lung injury; however, its underlying mechanism remains undefined. This study aimed to elucidate this mechanism. Thirty-two SD rats were divided into four groups and exposed to acrolein via tracheal instillation at doses of 0, 0.1, 1, and 10 mg/kg, respectively. Lung function and histopathology were assessed by invasive plethysmography and H&E staining; alveolar-capillary membrane permeability, tight junction ultrastructure, and tight junction protein levels were assessed by Evans blue extravasation, transmission electron microscopy, and Western blot, respectively. Acrolein exposure triggered severe, dose-dependent impairment of pulmonary function, with significantly elevated respiratory system resistance and tissue elastance, alongside reduced inspiratory capacity and quasi-static compliance. Histological examination revealed progressive alveolar architecture disruption, inflammatory infiltration, and intra-alveolar hemorrhage across all dose groups. Evans blue assay confirmed dose-related increases in pulmonary barrier permeability. Ultrastructural analysis showed pronounced disintegration of tight junctions between endothelial and epithelial cells, correlating with acrolein concentration. Concordantly, Western blot revealed dose-dependent downregulation of claudin-18, occludin, and ZO-1. Direct disruption of alveolar tight junctions by acrolein elucidates its mechanism of inhalation toxicity and identifies this process as a potential target for barrier-stabilizing interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.